Product Pipeline


Xenon is focused on advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression

Our lead molecule, azetukalner, is a novel, potent Kv7 potassium channel opener being developed for the treatment of epilepsy, major depressive disorder, and potentially other neurological disorders.

Our pre-clinical work leverages our deep ion channel expertise to develop promising drug candidates that target sodium and potassium channels.



Preclinical
Phase 1
Phase 2
Phase 3
Approved

Azetukalner (FOS)

for Focal Onset Seizures
X-TOLE2/3 Clinical Trial

Azetukalner (PGTCS)

for Primary Generalized Tonic-Clonic Seizures
X-ACKT Clinical Trial

Azetukalner (MDD)

for Major Depressive Disorder
X-NOVA Clinical trial

Azetukalner (MDD)

for Major Depressive Disorder
Investigator-led POC study (Mount Sinai)

Kv7 Program

Potassium Channel Openers

Nav1.7 Program

Sodium Channel Inhibitors

Nav1.1 Program

Sodium Channel Openers

Partnered

NBI-921352

for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences


Medical Affairs

Learn more about our ongoing clinical trials

View Medical Affairs
Publications

See publications related to our clinical development candidates

View Publications
Partners

Find out more about collaborating with Xenon

View Partners